Qian Xi Nan Bu Yi Zu Miao Zu Zi Zhi Zhou

Acute Aortic Syndrome (AAS) is a serious and life-threatening condition where inflammation significantly affects its development and progression, leading to high rates of death and complications. This research focuses on understanding how inflammation and anti-inflammatory treatments impact patients with AAS, particularly those undergoing surgery. The study is a large, long-term observational registry involving 20 cardiovascular centers in China, enrolling adult patients from 2016 through 2040 to investigate early and late outcomes related to inflammation. Participants in the study have undergone various treatments for AAS, including medical therapy, open surgery, endovascular repair, or hybrid procedures. The research collects detailed clinical data using specially designed forms and statistical analysis software to explore the role of inflammation and anti-inflammatory strategies alongside surgical repair. The registry also includes patients who had additional cardiac surgeries like coronary artery bypass or carotid artery replacement during their AAS treatment. During the study, researchers assess patients for severe inflammatory responses and organ function within the first week after surgery, and track outcomes such as mortality within 30 days, stroke, kidney injury, infections, bleeding, blood transfusions, and time spent in intensive care. The study aims to provide insights over 15 years on how inflammation affects recovery and long-term prognosis in AAS patients, helping to guide improved treatment strategies and reduce residual cardiovascular risks.

Objective: To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage. Design: This study is a multi-center, prospective, double-blinded, randomized controlled trial. Interventions: First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml of nicardipine hydrochloride is injected into the EVD or LD drain tube, followed by 2 ml of 0.9 % sodium chloride solution (NaCl), and then the EVD or LD tube was clamped for 2 hours after the injection was completed, then kept open as clinically necessary until the next dose (twice a day).